Seltorexant, also known as MIN-202/JNJ-42847922, developed by Janssen Research & Development, LLC and Minerva Neurosciences, is one of the several orexin-2 receptor antagonists approved for insomnia [137]. This evidence concerns the gene HCRTR2 and insomnia measurement.